Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immediate early response gene 5 protein (IER5)
- Target
- IER5
- Molecular classification
- Transcription factor, Immediate-early gene protein
01
Overview
Immediate early response gene 5 protein (IER5) is a 327-amino-acid transcription factor predominantly localized to the nucleus, quickly induced by stressors such as radiation, oncogenic signals, and heat shock[5][1][2][3]. IER5 regulates the cell cycle, inhibits cell proliferation by downregulating CDC25B, and mediates survival and stress responses via interaction with phosphatase PP2A and the heat shock factor HSF1[5][7]. It facilitates repair of DNA double-strand breaks through non-homologous end joining, and interacts with key DNA repair proteins PARP1 and Ku70[1]. IER5 is frequently upregulated in cancer types, modulating treatment responses and serving as a biomarker for radiation exposure and cancer prognosis[4][6][1]. Modulation of IER5 levels can influence therapeutic effects in cancer and its inhibition may present new therapeutic strategies[1][4].
- Other names
- Immediate-early response 5PP4583SBBI48Immediate early response gene 5 proteinIER5
02
Mechanism of action
Drugs targeting PARP1 (e.g., olaparib) may affect IER5-mediated DNA damage repair, potentially enhancing therapeutic effects/response in cancer
03
Biological functions
Cell cycle regulation (G2/M cell cycle checkpoint, CDC25B regulation, proliferation inhibition)DNA damage response and repair (non-homologous end-joining of double-strand breaks)Regulation of heat shock response and protein chaperoning (HSF1-dependent)Signal transduction (phosphorylation/dephosphorylation via PP2A, S6 kinase modulation)Cell survival and stress responseApoptosis modulation
04
Disease associations
Cancer (upregulated in tumors, associated with poor prognosis; biomarker; especially cervical, liver, lung, glioblastoma)Radiation response (used as a biodosimetry marker)Other (potential roles in mood disorders)
05
Safety considerations
Potential impact on normal cell cycle and DNA repair in healthy tissues during therapyPossible modulation of stress and apoptosis pathways complicating therapeutic targeting
06
Interacting drugs
Olaparib (PARP1 inhibitor, affects IER5 stability and DNA repair response)
07
Biomarkers
IER5 expression level (as a marker for radiation exposure, cancer prognosis, and DNA damage response)
Beyond the preview
Go deeper on Immediate early response gene 5 protein (IER5).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immediate early response gene 5 protein (IER5).